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ABSTRACT
Purpose. This study was designed to assess the impact of
age and comorbidity on choice and outcome of definitive
chemoradiotherapy (dCRT) or neoadjuvant chemoradio-
therapy plus surgery.
Methods. In this population-based study, all patients with
potentially curable EC (cT1N?/cT2-3, TX, any cN, cM0)
diagnosed in the South East of the Netherlands between
2004 and 2014 were included. Kaplan–Meier method with
log-rank tests and multivariable Cox regression analysis
were used to compare overall survival (OS).
Results. A total of 702 patients was included. Age
C 75 years and multiple comorbidities were associated
with a higher probability for dCRT (odds ratio [OR] 8.58;
95% confidence interval [CI] 4.72–15.58; and OR 3.09;
95% CI 1.93–4.93). The strongest associations were found
for the combination of hypertension plus diabetes (OR
3.80; 95% CI 1.97–7.32) and the combination of cardio-
vascular with pulmonary comorbidity (OR 3.18; 95% CI
1.57–6.46). Patients with EC who underwent dCRT had a
poorer prognosis than those who underwent nCRT plus
surgery, irrespective of age, number, and type of
comorbidities. In contrast, for patients with squamous cell
carcinoma with C 2 comorbidities or age C 75 years, OS
was comparable between both groups (hazard ratio [HR]
1.52; 95% CI 0.78–2.97; and HR 0.73; 95% CI 0.13–4.14).
Conclusions. Histological tumor type should be acknowl-
edged in treatment choices for patients with esophageal
cancer. Neoadjuvant chemoradiotherapy plus surgery should
basically be advised as treatment of choice for operable
esophageal adenocarcinoma patients. For patients with
esophageal squamous cell carcinoma with C 2 comorbidi-
ties or age C 75 years, dCRT may be the preferred strategy.
For potentially curable esophageal cancer (EC), radical
surgery after neoadjuvant chemoradiotherapy (nCRT) has
been the standard of care in the Netherlands since 2008.1
However,surgeryisassociatedwithpostoperativemorbidityin
up to60% ofpatientswitha 90-daymortality rateof7–13%.2–6
In general, comorbidity and older age are related to early
postoperative mortality after gastrointestinal cancer surgery.7
A less aggressive treatment approach may be considered in
these patients.8 Definitive chemoradiotherapy (dCRT) is an
alternative curative intended treatment option in elderly
patientsandinpatientswithseverecomorbidities.3,9–11Similar
survivalrateshavebeenreportedafterchemoradiotherapywith
or without surgery for patients with esophageal squamous cell
carcinoma (ESCC).11,12 In patients with esophageal adeno-
carcinoma (EAC), surgery is recommended unless there is a
high risk for threatening postoperative complications and/or
mortality.13–16
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Long-term outcome data following dCRT for potentially
curable EC are scarce and guidelines for selecting the
appropriate treatment in patients with severe comorbidity
and older age are not available.13,17 The purpose of this
population based, retrospective study was to assess the
impact of age and comorbidity on the choice of curative
intended treatment and long-term overall survival among
patients with potentially curable esophageal cancer.
PATIENTS AND METHODS
Data from all patients with a primary esophageal cancer
(CI 5.1–5.9), diagnosed between 2004 and 2014 in the
South East of the Netherlands, were obtained from the
population-based nationwide Netherlands Cancer Registry
(NCR). Data from this region was used, because data on
comorbidities was not routinely registered by the NCR in
other parts of the Netherlands during the study period.
Trained data managers of the NCR routinely extract
information on diagnosis, tumor stage, comorbidity, and
treatment from the medical hospital records, using a strict
registration and coding manual. Tumors were clinically
staged according to the UICC/AJCC TNM classification
that was valid at the time of diagnosis.
Patients with potentially curable EC (cT1N?/cT2-3,
TX, any cN, cM0) and treated with dCRT or nCRT plus
surgery were eligible for this study (Fig. 1). Patients were
classified as cTX when the tumor could not be sufficiently
Excluded n=1141 *
- Neuroendocrine tumors n=35 **
- Cervical esophageal cancer n=26***
- Distant metastasis (cM1/cM1b) n=913
- cT1N0 n=113 ****
- Tumors invading adjacent structures (cT4/ 
cT4a/ cT4b) n=187 
Co-morbidity unknown n=63 
n=1575
n=1512
Patients with potentially curable 
esophageal cancer 
(cT1N+/cT2 -3,TX, any N, M0 ) who 
underwent definitive 
chemoradiotherapy or neoadjuvant  
chemoradiotherapy plus surgery: n=702 
Excluded n=810
- Surgery only n=209
- Other treatment n=379*****
- No treatment n= 219
- Treatment unknown n=3
All esophageal cancer patients 
diagnosed between 2004-2014 in the  
South E ast of the Netherlands.
n=2716
FIG. 1 Flowchart of study population. *The sum of excluded
patients per exclusion criteria is larger than the total number of
excluded patients because some patients met two exclusion criteria.
**Lymphoma, melanoma were already excluded. ***Not eligible for
surgery. ****Eligible for endoscopic resection. *****74% underwent
radiotherapy only
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subcategorized, for example due to an obstructing tumor
that could not be passed during endoscopic ultrasonogra-
phy. Patients were considered potentially curable if they
had clinically no distant metastasis (cM0 according to
TNM-7 and cM1a, i.e., positive coeliac nodes, according to
TNM-6), and no tumor invasion into surrounding organs
(no cT4 according to TNM-6 and no cT4a or cT4b
according to TNM-7). Although patients with a cT4a tumor
could theoretically be treated with curative intent, all cT4
tumors were excluded, because they were only distin-
guished after 2010 by TNM-7. For the analysis, patients
with a cM1a tumor according to TNM-6 were categorized
as having cN? according to TNM-7. As of 2010, coding
regulations to register a cM0 or cM1 status into the NCR
were less strict than before 2010. As a consequence, since
2010, relatively more patients were registered with no
(cM0) rather than unknown clinical distant metastases into
the NCR. To account for this, we decided to include all
patients with cMX. Patients with cervical esophageal
cancer (CI 5.0) and those with a cT1N0 tumor were
excluded, because surgery was not standard care in these
patients. Patients who underwent palliative or other treat-
ment were excluded from the analysis (Fig. 1).
In this study, neoadjuvant CRT with curative intent
consisted of 5 cycles of carboplatin (area under the curve
2 mg/ml/min)/paclitaxel 50 mg/m2 and 41.4 Gy/1.8 Gy or
occasionally 50.4 Gy/1.8 Gy radiotherapy followed by
potentially curative surgery, based on the CROSS regi-
men.1,18 Definitive or primary CRT usually included
concurrent chemotherapy (cisplatin/5-FU or carbo-
platin/paclitaxel) and radiotherapy[ 50.4 Gy/1.8–2 Gy as
first treatment in patients who were unable to undergo
surgical resection.19,20 In the analysis, patients with pri-
mary intended nCRT of 41.4–50.4 Gy/1.8 Gy in whom
additional surgical resection was denied because of dete-
riorated medical condition and potentially high risk for
severe morbidity and mortality.
In the NCR, comorbidities were registered according to
a slightly modified version of the Charlson comorbidity
index.21 The Charlson comorbidity index is most widely
used for recording comorbidity and was validated in vari-
ous studies. Comorbidity was defined as life-shortening
diseases that were present at the time of cancer
diagnosis.22–24
The following groups of comorbidities were included in
our analyses: pulmonary disease (COPD, emphysema,
chronic bronchitis), cardiovascular disease (angina pec-
toris, myocardial infarction, cardiomyopathy, myocarditis,
vascular disease, TIA, CVA), hypertension, diabetes mel-
litus, and previous invasive malignancies. Patients with no
serious comorbidity in the medical file were registered as
having no comorbidity. Patients were excluded if comor-
bidity status was not registered.
Statistics Netherlands developed an indicator of Socio-
Economic Status Score (SES), using individual fiscal data
based on the economic value of the home and household
income. This SES indicator is provided at an aggregated
level for each postal code (covering an average of 17
households). SES was categorized as low (deciles 1–3),
medium (deciles 4–7), or high (deciles 8–10). A separate
category was made for postal codes of care-providing
institutions, because assigning SES for those living in
nursing home or other care providing institutions is
difficult.
Statistics
Differences between patient groups were analysed by
using Chi square tests. Multivariable logistic regression
analyses were performed to examine the impact of clini-
copathological factors on the choice of curative-intended
treatment (dCRT vs. nCRT followed by surgery). Survival
time was defined as time from 6 months after diagnosis
until death or until February 2017 for patients who were
still alive. Thus, patients who died within 6 months after
diagnosis were excluded from survival analysis. This was
done to deal with immortal time bias, i.e., the waiting
period of 6–8 weeks between end of CRT and surgery in
patients undergoing nCRT, because total treatment dura-
tion for those who underwent dCRT is shorter.25 Overall
survival (OS) was calculated with the Kaplan–Meier
analysis, and log-rank tests were performed to test for
differences between groups. Multivariable survival analy-
ses were performed using the Cox proportional hazards
model (HR and 95% confidence intervals) to investigate
the prognosis after dCRT versus nCRT plus surgery after
adjustment for confounders. According to histological
tumor type, separate models were performed for age cat-
egories, number of comorbidities, and for each type of
comorbidity. All analyses were performed in SAS version
9.4, and two-sided p values \ 0.05 were considered sta-
tistically significant.
RESULTS
Clinicopathological Characteristics
A total of 702 patients was included in the study
(Fig. 1). Neoadjuvant CRT with surgery was performed in
386 patients (55%) and dCRT in 316 patients (45%). Fre-
quently reported comorbidities were cardiovascular disease
(33%), hypertension (33%), pulmonary disease (15%), and
diabetes (15%; Table 1). Most tumors were adenocarci-
nomas (65%) and in a locally advanced stage with cT3
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(65%) and cN1-3 (60%). Approximately 81% of the
patients were treated after 2008.
Association Between Age and Treatment
Of the patients treated with nCRT and surgery, less than
8% (29/386 patients) were 75 years or older (Table 2),
whereas 19% (60/316) of the patients treated with dCRT
were younger than 60 years. Approximately 78% (102/131
patients) of the elderly (C 75 years) patients were treated
with dCRT, whereas only 33% (60/184 patients) of the
patients younger than 60 years underwent dCRT.
Association Between Comorbidity and Treatment
Patients with multiple comorbidities underwent more
often dCRT (160/273 patients; 59%), whereas patients
without comorbidities more often underwent nCRT plus
surgery (142/211 patients; 67%; Table 2).
Multivariable logistic regression analysis confirmed the
associations of age and comorbidities with type of treat-
ment. Patients C 75 years of age (odds ratio [OR] 8.58;
95% confidence interval [CI] 4.72–15.58) and patients with
multiple comorbidities (OR 3.09; 95% CI 1.93–4.93) had a
higher probability to receive dCRT than nCRT plus sur-
gery. Regarding type of comorbidity and the likelihood to
receive dCRT, the association was higher for the combi-
nation hypertension and diabetes (OR 3.80; 95% CI
1.97–7.32) and for cardiovascular with pulmonary comor-
bidity (OR 3.18; 95% CI 1.57–6.46; Table 2).
Long-Term Overall Survival
Two-year overall survival (OS) of all patients was sig-
nificantly better following nCRT plus surgery compared
with dCRT (61% vs. 38%; p\ 0.01). Even after stratifi-
cation for histological tumor type, the survival differences
remained statistically significant (EAC: 60% vs. 33%
respectively, p\ 0.01; ESSC: 68% vs. 42% respectively,
p\ 0.01; Fig. 2a).
TABLE 1 Characteristics of esophageal cancer patients (cT1N?/
cT2-3,TX, any cN, cM0) treated with definitive chemoradiotherapy or
neoadjuvant CRT followed by surgery diagnosed in the South East of
the Netherlands in the period 2004–2014 (N = 702)
All patients (N = 702)
N %
Treatment
dCRT 316 45
nCRT ? surgery 386 55
Gender
Male 535 76
Female 167 24
Age (year)
\ 60 184 26
60–74 387 55
C 75 131 19
Number of comorbidities
0 211 30
1 218 31
C 2 273 39
Type of comorbidity
Cardiovascular 231 33
Pulmonary 108 15
Hypertension 232 33
Previous malignancies 72 10
Diabetes 102 15
Socioeconomic status
Low 153 22
Intermediate 277 39
High 219 31
Care providing institution 21 3
Unknown 32 5
Tumor localization
Proximal 38 5
Mid 92 13
Distal 544 77
Overlapping/not otherwise specified 28 4
Histology
EAC 457 65
ESCC 230 33
Other/unknown 15 2
cT classification
T1 6 \ 1
T2 138 20
T3 455 65
TX 103 15
cN classification
N0 259 37
N? 423 60
NX 20 3
TABLE 1 continued
All patients (N = 702)
N %
Period of diagnosis
2004–2008 133 19
2009–2014 569 81
EAC esophageal adenocarcinoma; ESCC esophageal squamous cell
carcinoma; dCRT definitive chemoradiotherapy; nCRT neoadjuvant
chemoradiotherapy
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TABLE 2 Multivariable logistic regression analysis of clinicopatho-
logical factors upon the likelihood of treatment with dCRT versus
nCRT followed by surgery among patients with esophageal cancer
(cT1N?/cT2-3,Tx, any cN, cM0) diagnosed in the South East of the
Netherlands in the period 2004–2014 (N = 702)
Patients p value Multivariable analysis
dCRT (n = 316) nCRT ? surgery (n = 386) dCRT versus nCRT ? surgery
N % N % OR 95% CI
Gender \ 0.01
Male 218 69 317 82 1.0
Female 98 31 69 18 1.38 0.88–2.17
Age (year) \ 0.01
\ 60 60 19 124 32 1.0
60–74 154 49 233 60 1.08 0.69–1.68
C 75 102 32 29 8 8.58 4.72–15.58
Number of comorbidities \ 0.01
0 69 22 142 37 1.0
1 87 28 131 34 1.34 0.84–2.15
C 2 160 51 113 29 3.09 1.93–4.93
Type of comorbiditya
Cardiovascular 132 42 99 26 \ 0.01 1.74 1.18–2.57
Pulmonary 63 20 45 12 \ 0.01 2.08 1.28–3.38
Hypertension 118 37 114 30 0.03 1.40 0.95–2.06
Previous malignancies 44 14 28 7 \ 0.01 1.55 0.86–2.80
Diabetes 60 19 42 11 \ 0.01 2.39 1.45–3.92
Cardiovascular and pulmonary 34 11 17 4 \ 0.01 3.18 1.57–6.46
Hypertension and diabetes 40 13 18 5 \ 0.01 3.80 1.97–7.32
Socioeconomic status 0.05
Low 79 25 74 19 1.0
Intermediate 125 40 152 39 0.67 0.42–1.06
High 84 27 135 35 0.57 0.35–0.93
Care providing institution/unknown 28 9 25 6 0.72 0.34–1.55
Tumor localization \ 0.01
Proximal/mid 98 31 32 8 1.0
Distal 204 65 340 88 0.23 0.13–0.40
Overlapping/not otherwise specified 14 4 14 4 0.37 0.14–0.98
Histologyb \ 0.01
EAC 158 50 299 77 1.0
ESCC 149 47 81 21 1.95 1.24–3.06
cT classification \ 0.01
cT1-2 70 22 74 19 1.0
cT3 184 58 271 70 0.66 0.42–1.03
cTX 62 20 41 11 1.34 0.72–2.48
cN classification 0.07
cN0 112 35 147 38 1.0
cN? 190 60 233 60 1.76 1.17–2.66
cNX 14 4 6 2 3.36 1.03–10.97
Period of diagnosis 0.01
2004–2008 60 23 73 16 1.0
2009–2014 326 77 243 84 0.48 0.35–0.76
EAC esophageal adenocarcinomas; ESCC esophageal squamous cell carcinoma; dCRT definitive chemoradiotherapy; nCRT neoadjuvant
chemoradiotherapy; OR odds ratio; CI confidence interval
aThe effects of type of comorbidity on treatment allocation were evaluated in separated models, which are adjusted for all variables in Table 2
expect number of comorbidities. Reference category for effects of type of comorbidity: No comorbidity
bCategory unknown is not shown
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Impact of Age and Comorbidity on Long-Term Overall
Survival
Kaplan–Meier survival analysis showed that the 2-year
OS was worse among patients with EAC who underwent
dCRT compared with those who underwent nCRT plus
surgery, regardless of the number of comorbidities
(Fig. 2b). In contrast, the 2-year OS for ESCC patients with
multiple comorbidities after dCRT (46%) was comparable
to the 2-year OS (51%) following nCRT plus surgery
(Fig. 2c).
Multivariable Cox regression analyses showed that EAC
patients had a poorer prognosis following dCRT compared
with nCRT plus surgery, irrespective of age and number of
comorbidities (Table 3). Especially, among patients with
cardiovascular diseases, hypertension or diabetes survival
was poorer after dCRT.
In contrast, among ESCC patients with C 2 comor-
bidities or age C 75 years, OS after dCRT was comparable
to OS after nCRT plus surgery. This was especially the
case among ESCC patients with cardiovascular diseases or
previous malignancies. However, ESCC patients with
hypertension as the only comorbidity had a poorer OS after
dCRT compared with nCRT plus surgery. The impact of
pulmonary diseases or diabetes could not be assessed
accurately due to the small number of patients (Table 3).
DISCUSSION
The results of this population-based study support the
use of nCRT plus surgery in operable patients with EAC,
which was associated with a better overall survival
regardless of age, number and type of pretreatment
comorbidities. The administration of dCRT was preferable
in patients with ESCC with at least two comorbidities or
age C 75 years, because there were no differences in
overall survival than with nCRT plus surgery in these
patients. This was seen particularly among those with
cardiovascular diseases or previous malignancies as their
overall survival after dCRT was comparable to the overall
survival for patients after nCRT plus surgery.
In the Netherlands, nCRT in combination with surgery is
the standard potentially curative treatment for locally
advanced esophageal cancer. This treatment potentially
downstages the tumor and increases the radical
resectability (R0) rate, which in turn reduces locoregional
recurrences with improved long-term survival.1 Moreover,
the regimen of the CROSS trial also showed control of
distant disease beyond the first 24 months after nCRT,
supporting a direct systemic effect.25
Of great importance for a prolonged survival is a
pathological complete response following nCRT, which
occurred in 49% of the patients with ESSC included in the
CROSS trial and in 23% of those with EAC.1
In our study, 78% of the elderly patients were treated
with dCRT and survival in elderly patients with ESCC was
equal for both treatment modalities. Elderly patients are
generally regarded as less suitable for surgery because of
advanced age (C 75 years), comorbidity severity or
decreased performance status. Moreover, dCRT seems a
well-tolerated alternative for patients with EC who are not
fit enough to undergo surgery.1,7,11,12,17,22,23,26,27 Never-
theless, selecting the appropriate treatment for elderly
patients requires the presence a consulted geriatric physi-
cian in the multidisciplinary board.28
A relatively good outcome was reported after dCRT in
selected groups of patients.12,29–32 Two studies have found
a comparable OS after dCRT compared with surgery alone
for patients with resectable ESCC.11,12 However, in these
studies, survival differences were not investigated accord-
ing to number and type of comorbidities. We found no
significant difference in OS following dCRT or nCRT plus
surgery in patients with ESCC having at least two
comorbidities. This suggests that patients derive the same
benefits from both treatment methods, although the type of
comorbidity may have an impact on the outcome.
In patients with EAC, the standard approach of nCRT
followed by surgery indeed resulted in a better survival,
which also was found in the group with diabetes mellitus,
hypertension, or cardiovascular disease. Tougeron et al.
reported a more frequent use of dCRT in advanced staged
EAC, in elderly patients and those with comorbidities of
Charlson score C 2.13 Despite selection bias may be pre-
sent, survival after surgery was better compared with
survival after dCRT (median overall survival 36.2 vs.
16.5 months; P = 0.02). Another study has found a sig-
nificant improvement in median survival for patients with
locally advanced EAC treated with nCRT followed by
surgery compared with dCRT.14
These differences in treatment response between
patients with EAC and ESCC may be associated with
tumor aggressiveness and different carcinogenesis.13
Moreover, tumor site (distal vs. proximal) and pulmonary
based differences with larger fields of radiotherapy in
lower esophageal tumors also may play a role in outcome
differences between EAC and ESCC following dCRT.33
With current radiation techniques, including intensity-
modulated radiotherapy (IMRT), direct simulation based
on 3D or 4D planning CT, respiratory gated radiotherapy,
and intensity-modulated proton therapy the radiation dose
can be accurately delivered with less damage to normal
tissues.15,33–36 Moreover, in diminishing toxicity of
chemotherapy regimens, the combination of
Impact of Age and Comorbidity and the Treatment Choice in Esophageal Cancer 991
Months after diagnosis
)
%(lavivrusllarev
O
0 6 12 18 24 30 36
0
10
20
30
40
50
60
70
80
90
100
EAC (n=283)
ESCC  (n=78)
EAC (n=141)
ESCC (n=127)
nCRT + surgery
dCRT
a
Months after diagnosis
)
%(lavivrusllare v
O
0 6 12 18 24 30 36
0
10
20
30
40
50
60
70
80
90
100
1 co-morbidity (n=98)
0 co-morbidities (n=105)
1 co-morbidity (n=32)
> 2 co-morbidities (n=80)
> 2 co-morbidities (n=90)
0 co-morbidities (n=29)
nCRT + surgery
dCRT
b
Months after diagnosis
)
%(lavivrusllarev
O
0 6 12 18 24 30 36
0
10
20
30
40
50
60
70
80
90
100
1 co-morbidity (n=26)
0 co-morbidities (n=33)
1 co-morbidity (n=39)
> 2 co-morbidities (n=57)
> 2 co-morbidities (n=19)
0 co-morbidities (n=31)
nCRT + surgery
dCRT
c
FIG. 2 a Overall survival of patients (cT1N?/cT2-3,Tx, any N,
M0) according to morphology following dCRT or nCRT followed
by surgery (n = 205). Patients who died within the first 6 months
after diagnosis were excluded from the analysis. b Overall survival
of EAC patients (cT1N?/cT2-3,Tx, any N, M0) according to the
number of comorbidities following dCRT or nCRT followed by
surgery (n = 424). Patients who died within 6 months after
diagnosis were excluded from the analysis. c Overall survival of
ESCC patients (cT1N?/cT2-3,Tx, any N, M0) according to number
of co-morbidities following dCRT or nCRT followed by surgery
(n = 205). Patients who died within the first 6 months after
diagnosis were excluded from the analysis
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carboplatin/paclitaxel has shown to be a good alternative or
even the standard approach in dCRT, especially in patients
with cardiovascular and pulmonary comorbidities.37
Our study has some limitations. First, the intent of
curative treatment with chemoradiotherapy (primary dCRT
or nCRT) was uncertain in this retrospective study. As
patients with M1 disease were excluded, it was assumed
that chemoradiotherapy was given with curative intent in
all included patients. However, a small subset of patients
were not fit enough or unable to undergo the planned
surgery after nCRT and were treated with CRT alone or
allocated to the dCRT group. This may lead to a less
homogeneous group of patients treated with dCRT.
Moreover, of the excluded EC patients who had surgery
alone (Fig. 1), surgery could had been still a treatment
options for some patients not suitable for chemoradio-
therapy. As reported, a considerable number of these
patients were not eligible for surgery due high age
([ 75 years) and serious multiple comorbidities, the OS
was worse after surgery alone in a previous analysis of
potentially curable EC patients (n = 1,184) during
1995–2013.2,3,19 The 3-year OS in patients with EAC after
surgery alone was worse but comparable among those with
C 2 comorbidities after dCRT (HR 1.07; 95% CI
0.72–1.60). The 3-year OS among ESCC patients after
dCRT was comparable with those after surgery alone,
despite the number of comorbidities, and even more
favourable in those with pulmonary disease (HR 0.81; 95%
CI 0.32–0.71).38 Second, limited information was given
about the radiotherapy techniques and schedules of the
given chemoradiotherapy. Since 2004, however, there was
an increased preference for carboplatin/paclitaxel with less
severe toxicity (6%) compared with cisplatin/5-FU (15%)
as standard regimen in dCRT, especially in patients with
cardiovascular comorbidity.37 Third, the impact of type of
some comorbidities could not be assessed accurately due to
a small number of patients. Moreover, information about
the performance status was not registered for the study
period. Furthermore, the accuracy of the diagnostic and
staging methods used is unknown, while endoscopic
ultrasonography was not always possible in patients with
EC leading to unknown reported clinical T-stage in 15% of
patients. Although out of the scope of this study, salvage
surgery in solitary localized recurrences or persistent dis-
ease after CRT could be a curative option in selective
cases. However, these procedures were not registered
accurately at that time, because intensive follow-up was
not commonly performed, and these procedures were then
only performed occasionally in special centers.19
TABLE 3 Multivariable Cox regression analyses to examine overall survival differences among patients who underwent dCRT versus patients
who underwent nCRT followed by surgery according to age, number, and type of comorbidity, stratified for histology
EAC ESSC
N HR of dCRT versus
nCRT ?surgery
95% CI N HR of dCRT versus
nCRT ? surgery
95% CI
Patients who died within 6 months after diagnosis were excluded to reduce immortal time bias
Number of comorbidities*
0 comorbidities 134 3.21 1.85–5.57 64 4.14 1.80–9.52
1 comorbidity 130 2.99 1.73–5.19 65 2.31 1.10–4.89
C 2 comorbidities 160 2.67 1.75–4.09 76 1.52 0.78–2.97
Age (year)**
\ 60 116 4.95 2.63–9.32 55 2.30 1.09–4.85
60–74 230 2.33 1.63–3.34 117 2.72 1.58–4.69
75? 78 2.17 1.09–4.30 33 0.73 0.13–4.14
Type of comorbiditya
Cardiovascular diseases 131 2.32 1.42–3.77 67 1.68 0.83–3.40
Pulmonary 64 1.84 0.90–3.78 32 n.a.
Hypertension 142 3.34 2.10–5.34 62 3.22 1.22–8.50
Previous malignancies 33 1.30 0.36–4.67 28 0.98 0.25–3.90
Diabetes 69 2.95 1.50–5.81 16 n.a.
n.a. not assessed (too small number of patients), HR hazard ratio, CI confidence interval
*Adjusted for gender, age, tumor stage, and period of diagnosis
**Adjusted for gender, tumor stage, number of comorbidities and period of diagnosis
aModels for type of comorbidity were adjusted for gender, age, tumor stage, period of diagnosis, and number of comorbidities
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The strength of this population-based study is that the
results are based on patients diagnosed in ten hospitals
providing an overview of everyday clinical practice, rather
than single-institution results in which patients are possibly
more carefully selected.
In conclusion, neoadjuvant chemoradiotherapy plus
surgery should basically be advised in operable patients
with potentially curable esophageal adenocarcinoma
regardless of age, number, and the type of comorbidities.
Definitive CRT may be preferred in patients with esopha-
geal squamous cell carcinoma having at least two
comorbidities or being older than 75 years. For a better
selection of patients, who may benefit from dCRT,
prospective studies are needed.
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